semaglutide and tirzepatide for weight loss vs GLP-1 Medications for Weight Loss:

Phase 1b studies in patients with type 2 diabetes demonstrated proof-of-concept efficacy, with dose-dependent reductions in fasting plasma glucose and postprandial glucose excursions over 28 days of treatment

Congenital Lymphedema refers to symptoms that develop in early childhood

Maintenance dosing is typically appropriate when a patient has reached targeted clinical or individual weight loss goals and approached a plateau point where there is no active weight loss or weight regain, says Gitanjali Srivastava, MD, medical director of Vanderbilt Obesity Medicine

While many individuals reach their goals using a personalized program that features a single medication, a combination approach might be explored for: The Slow Responder: Someone who has been on a therapeutic dose of semaglutide for several months but has not seen the expected weight loss results

The rising global prevalence of T2DM and obesity makes understanding the full range of benefits and risks associated with GLP-1 RAs essential for optimizing treatment strategies in these populations